Compare TKO Group Holdings Inc (TKO) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

TKO trades at $179.38, up 0.41% on the day, but technical indicators signal a bearish trend with the stock near a 52-week low of $174.58 (Defense World, 2026-10-02). The company reported mixed Q2 2026 earnings, missing EPS estimates but raising full-year guidance. Revenue growth remains solid, with 2026 projections at $5.3B, though profitability margins are thin at 4.33% net income margin. A quarterly dividend of $0.79 was declared for payment in September 2026.

Wall Street maintains a bullish stance with 89% buy ratings and a $227 consensus price target, implying significant upside. Key risks include execution on media rights deals, competitive pressures in sports entertainment, and reliance on live events. The stock's high P/E of 63.73 suggests growth expectations must be met to justify valuation.

Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.

The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.